BAD HOMBURG, Germany, Oct. 28, 2003 (PRIMEZONE) -- Fresenius Medical Care AG ("FME") (Frankfurt Stock Exchange:FME) (Frankfurt Stock Exchange:FME3) (NYSE:FMS) (NYSE:FMS_p), the world's largest provider of Dialysis Products and Services, has been informed that Goldman Sachs is managing a sale of 7.68 million Fresenius Medical Care AG preference shares for a group of shareholders in an accelerated bookbuilding offering.
Goldman Sachs and other investors acquired the preference shares from the Company in March of 2000. Since then, these shares have been reflected in the Company's financial statements as issued and outstanding. In addition, these shares were initially subject to a two-year restricted sale agreement, which expired in March of 2002.
Dr. Ben Lipps, the Chief Executive Officer of Fresenius Medical Care, stated that, "I am delighted that one of the Company's principal objectives for the 2000 share placement has been achieved. I look forward to more trading in the Company's preference shares, thereby increasing liquidity and trading volume."
Fresenius Medical Care AG is the world's largest, integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,200,000 individuals worldwide. Through its network of approximately 1,510 dialysis clinics in North America, Europe, Latin America and Asia-Pacific, Fresenius Medical Care provides Dialysis Treatment to approximately 115,800 patients around the globe. Fresenius Medical Care is also the world's leading provider of Dialysis Products such as hemodialysis machines, dialyzers and related disposable products. For more information about Fresenius Medical Care, visit the Company's website at http://www.fmc-ag.com.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG does not undertake any responsibility to update the forward-looking statements in this release.
HTML: http://newsroom.eworldwire.com/wr/102803/1835.htm
PDF: http://newsroom.eworldwire.com/pdf/102803/1835.pdf
ONLINE NEWSROOM: http://newsroom.eworldwire.com/1722.htm